Navigation Links
Barr Confirms Filing an Application With a Paragraph IV Certification for Femcon(R) FE Chewable Oral Contraceptive Product
Date:8/19/2007

ration of our financial statements; the impact of competitive products and pricing on products, including the launch of authorized generics; the ability to launch new products in the timeframes we expect; the availability of raw materials; the availability of any product we purchase and sell as a distributor; the regulatory environment in the markets where we operate; our exposure to product liability and other lawsuits and contingencies; the increasing cost of insurance and the availability of product liability insurance coverage; our timely and successful completion of strategic initiatives, including integrating companies (such as PLIVA d.d.) and products we acquire and implementing our new SAP enterprise resource planning system; fluctuations in operating results, including the effects on such results from spending for research and development, sales and marketing activities and patent challenge activities; the inherent uncertainty associated with financial projections; our expansion into international markets through our PLIVA acquisition, and the resulting currency, governmental, regulatory and other risks involved with international operations; our ability to service our significantly increased debt obligations as a result of the PLIVA acquisition; changes in generally accepted accounting principles; and other risks detailed in our SEC filings, including in our Transition Report on Form 10-K/T for the six months ended December 31, 2006.

The forward-looking statements contained in this press release speak only as of the date the statement was made. The Company undertakes no obligation (nor does it intend) to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except to the extent required under applicable law.


'/>"/>
SOURCE Barr Pharmaceuticals, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3

Related biology technology :

1. Stratagenes Human cDNA Microarrays: Perform Gene Expression Profiling and Discover New Genes
2. The Flexible matriXarray Chip System: A New Perspective for Probe Optimization in Gene-Expression Profiling
3. Ambion Offers Gene Expression Profiling Service
4. Novel MicroRNA Array Technology for Sensitive miRNA Profiling
5. MicroRNA Profiling by Array Analysis Reveals Critical BioMarkers
6. Total RNA from Whole Blood for Expression Profiling
7. Unmask Blood RNA for Gene Expression Profiling
8. Proteomics in Bladder Cancer Research: Protein Profiling of Bladder Squamous Cell Carcinomas, Rev C
9. Microgenomic Expression Profiling
10. Laser Capture Microdissection (LCM) and Expression Profiling of Long-Range Projection Neurons
11. A Novel Process for Gene Expression Profiling of Rat and Mouse Tissues from Formalin-Fixed Paraffin-Embedded Sections Using Microarrays
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... ... 2015 , ... Matrix Marketing Group, LLC , a leading provider of ... head up its account management department as vice president of client services. Amanda ... account management and delivery expertise to the growing Matrix Marketing Group team in Denver, ...
(Date:6/30/2015)... June 30, 2015 /PRNewswire/ - RepliCel Life Sciences ... regenerative medicine company focused on the development of ... in its Phase 1/2 clinical trial of RCT-01, ... Achilles tendinosis, has been enrolled and their tissue ... injections. RCT-01 is comprised of non-bulbar dermal sheath ...
(Date:6/30/2015)... ... 2015 , ... Smarter Alloys today announced a final round ... allows orthodontists to simultaneously apply different forces to different teeth. The additional case ... about taking SmartArch one step closer to commercial availability for orthodontists and dentists,” ...
(Date:6/29/2015)... , June 30, 2015   Pharnext SAS ... being developed for the treatment of Charcot-Marie-Tooth Type 1A (CMT1A), ... at the 2015 Peripheral Nerve Society (PNS) Biennial Meeting at ... , June 27 - July 2, 2015. ... on Wed July 1, 5p.m. to 7p.m. EDT: ...
Breaking Biology Technology:Matrix Marketing Group Expands Client Services Team 2RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 2RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 3RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 4New case studies for SmartArch orthodontic archwire paves way to product launch later this year 2Pharnext's PXT-3003 Featured in Multiple Presentations at 2015 Peripheral Nerve Society Biennial Meeting 2
... 22, 2011 NeurogesX, Inc. (Nasdaq: NGSX ... management therapies, today announced that on July 21, 2011 ... with a private placement to a group of institutional ... expected to receive approximately $20 million in gross proceeds ...
... a significant threat to humans, as emphasized by the recent ... published on July 21st by the Cell Press journal ... of similar and divergent strategies that different toxins use to ... toxic protein derived from the castor bean plant that has ...
... ViroPharma Incorporated,s (Nasdaq: VPHM ) second quarter ... Thursday, July 28, 2011 before the open of the U.S. ... call and live audio webcast at 9:00 a.m. Eastern Time ... will discuss the 2011 second quarter financial results and other ...
Cached Biology Technology:NeurogesX, Inc. Announces $20 Million Private Placement 2NeurogesX, Inc. Announces $20 Million Private Placement 3NeurogesX, Inc. Announces $20 Million Private Placement 4Targeting toxin trafficking 2ViroPharma to Release 2011 Second Quarter Financial Results on July 28, 2011 2
(Date:6/24/2015)... 24, 2015 Biometry authentication provider KeyLemon ... password solution one face in. ... one face in, entering the expanding biometric authentication ... multifactor-authentication biometric answer to the password problem. With ... partnership with KeyLemon, one face in allows users ...
(Date:6/23/2015)... June 23, 2015   Valencell, a ... results of a recent study that illustrates its ... wrist during activity. In a study conducted at ... along with the Apple Watch against a chest ... rate during activity. The study demonstrated that Valencell,s ...
(Date:6/18/2015)... Conn. , June 18, 2015 NXT-ID, Inc. ... authentication company focused on the growing mobile commerce market announces ... a featured segment on "Money on the Mark", scheduled to ... City June 20 th . ... will be from 7:00 to 8:00pm EST. NXT-ID, Inc.,s CEO ...
Breaking Biology News(10 mins):KeyLemon Announces Partnership With Biometric Password Solution onefacein 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 3NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 2NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 3
... factor for stroke, and its occurrence is closely related ... animals have shown that scavenger receptor class B type ... of scavenger receptor class B type I gene polymorphisms ... the exon 8 C1050T polymorphism, and these polymorphic loci ...
... During the last decade, our understanding of ... novel hypothalamic Arg-Phe-amide- related peptides, kisspeptin and ... the reproductive axis. Kisspeptins are currently recognized ... hypothalamus-pituitary-gonadal axis. Kisspeptin and its receptor, G ...
... The Bert L. and N. Kuggie Vallee Foundation announces, ... The 2013 winners are: Dr. Kirsty L. ... Molecular Biology at the Karolinska Institutet (Stockholm, Sweden) who ... fat cells. Dr. David Tobin, Assistant Professor of ...
Cached Biology News:
One-step, microplate or cuvet, colorimetric, linear detection range 6 mg/dL to 100mg/dL. Procedure: 15 min....
assays for phosphatase, lipase, nucleoside triphosphatases (ATPase, GTPase etc). HTS and follow up studies for phosphatase inhibitors. Quantitation of phosphate content in protein, lipids, and DNA....
assays for phosphatase, lipase, nucleoside triphosphatases (ATPase, GTPase etc). HTS and follow up studies for phosphatase inhibitors. Quantitation of phosphate content in protein, lipids, and DNA....
... Purpose -- The Varian 1200 ... highest level of flexibility and ... affordable, easy-to-use system. The complete ... guarantees success with today's applications ...
Biology Products: